LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) said high-level results from the
ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group,
showed Imfinzi did not achieve statistical significance for the primary endpoint
of disease-free survival versus placebo in early-stage non-small cell lung
cancer after complete tumour resection in patients whose tumours express PD-L1
on 25% or more tumour cells. The safety profile for Imfinzi was consistent with
its known safety profile.

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: 'We
are disappointed in the ADJUVANT BR.31 results. We are committed to addressing
the remaining unmet need in lung cancer through our broad development
programme.'

The company noted that Imfinzi is also being investigated as monotherapy and in
combinations in several other early-stage lung cancer settings, including in
medically inoperable or unresected Stage I-II NSCLC and unresectable, Stage III
NSCLC.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX